Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: The type 1 insulin-like growth factor receptor (IGF1R) plays a critical role in transformation, invasion and apoptosis protection, and is an attractive cancer treatment target. OBJECTIVE: To review IGF1R antibodies and kinase inhibitors that are in preclinical and clinical development, and to discuss questions that will influence the success of this approach in clinical practice. METHODS: This review is drawn from published literature, meeting abstracts and online resources. RESULTS/CONCLUSION: IGF1R blockade is generally well tolerated although it can induce hyperglycaemia. Single-agent activity has been documented in Ewing's sarcoma but not thus far in common solid tumours. Key issues include identification of factors that influence sensitivity to IGF1R blockade, and how most effectively to combine IGF1R inhibitors with other treatments.

Original publication




Journal article


Expert Opin Ther Targets

Publication Date





589 - 603


Animals, Antibodies, Monoclonal, Antineoplastic Agents, Apoptosis, Controlled Clinical Trials as Topic, Drug Delivery Systems, Drug Evaluation, Preclinical, Humans, Neoplasms, Protein Kinase Inhibitors, Protein-Tyrosine Kinases, Receptor, IGF Type 1